JP2021531245A5 - - Google Patents
Info
- Publication number
- JP2021531245A5 JP2021531245A5 JP2020572773A JP2020572773A JP2021531245A5 JP 2021531245 A5 JP2021531245 A5 JP 2021531245A5 JP 2020572773 A JP2020572773 A JP 2020572773A JP 2020572773 A JP2020572773 A JP 2020572773A JP 2021531245 A5 JP2021531245 A5 JP 2021531245A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- seq
- monoclonal antibody
- subject
- assay
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064335A JP2025100662A (ja) | 2018-07-10 | 2025-04-09 | 既存の相互作用を最小化する改変結合分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695988P | 2018-07-10 | 2018-07-10 | |
| US62/695,988 | 2018-07-10 | ||
| PCT/US2019/041203 WO2020014358A1 (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064335A Division JP2025100662A (ja) | 2018-07-10 | 2025-04-09 | 既存の相互作用を最小化する改変結合分子 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531245A JP2021531245A (ja) | 2021-11-18 |
| JP2021531245A5 true JP2021531245A5 (https=) | 2022-07-20 |
| JPWO2020014358A5 JPWO2020014358A5 (https=) | 2022-07-20 |
| JP7665339B2 JP7665339B2 (ja) | 2025-04-21 |
Family
ID=67544330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572773A Active JP7665339B2 (ja) | 2018-07-10 | 2019-07-10 | 既存の相互作用を最小化する改変結合分子 |
| JP2025064335A Pending JP2025100662A (ja) | 2018-07-10 | 2025-04-09 | 既存の相互作用を最小化する改変結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064335A Pending JP2025100662A (ja) | 2018-07-10 | 2025-04-09 | 既存の相互作用を最小化する改変結合分子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11448651B2 (https=) |
| EP (1) | EP3820891A1 (https=) |
| JP (2) | JP7665339B2 (https=) |
| KR (1) | KR102938177B1 (https=) |
| CN (1) | CN112543768B (https=) |
| AR (1) | AR115730A1 (https=) |
| AU (1) | AU2019302642B2 (https=) |
| BR (1) | BR112020026784A2 (https=) |
| CA (1) | CA3104873A1 (https=) |
| EA (1) | EA202190228A1 (https=) |
| IL (2) | IL316308A (https=) |
| MX (2) | MX2021000239A (https=) |
| MY (1) | MY202673A (https=) |
| SG (1) | SG11202012835RA (https=) |
| TW (2) | TW202428612A (https=) |
| WO (1) | WO2020014358A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| US20260008857A1 (en) * | 2024-06-13 | 2026-01-08 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008348252A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| WO2010122148A1 (en) | 2009-04-24 | 2010-10-28 | Boehringer Ingelheim International Gmbh | An improved antibody domain and antibody fragments and antibodies based thereon |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| WO2011074965A1 (en) | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| WO2012166588A2 (en) | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| SG2014010482A (en) * | 2011-08-17 | 2014-04-28 | Glaxo Group Ltd | Modified proteins and peptides |
| TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| BR112017004810A2 (pt) | 2014-11-05 | 2017-12-12 | Hoffmann La Roche | imunoensaio |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| AU2016344665C1 (en) * | 2015-10-29 | 2023-07-27 | F. Hoffmann-La Roche Ag | Anti-variant Fc-region antibodies and methods of use |
| US20170137535A1 (en) | 2015-10-30 | 2017-05-18 | Genentech, Inc. | Anti-factor d antibody formulations |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| WO2019101863A1 (en) | 2017-11-22 | 2019-05-31 | Vacara Ab | Antibodies to citrullinated proteins |
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| WO2020246891A1 (en) | 2019-06-07 | 2020-12-10 | Sanquin Innovatie B.V. | Methods and compounds for typing rheumatoid factors |
-
2019
- 2019-07-10 AU AU2019302642A patent/AU2019302642B2/en active Active
- 2019-07-10 CA CA3104873A patent/CA3104873A1/en active Pending
- 2019-07-10 AR ARP190101943A patent/AR115730A1/es unknown
- 2019-07-10 US US16/507,880 patent/US11448651B2/en active Active
- 2019-07-10 JP JP2020572773A patent/JP7665339B2/ja active Active
- 2019-07-10 KR KR1020217002619A patent/KR102938177B1/ko active Active
- 2019-07-10 WO PCT/US2019/041203 patent/WO2020014358A1/en not_active Ceased
- 2019-07-10 MX MX2021000239A patent/MX2021000239A/es unknown
- 2019-07-10 IL IL316308A patent/IL316308A/en unknown
- 2019-07-10 EA EA202190228A patent/EA202190228A1/ru unknown
- 2019-07-10 TW TW113110335A patent/TW202428612A/zh unknown
- 2019-07-10 TW TW108124293A patent/TWI838388B/zh active
- 2019-07-10 EP EP19749878.5A patent/EP3820891A1/en active Pending
- 2019-07-10 SG SG11202012835RA patent/SG11202012835RA/en unknown
- 2019-07-10 CN CN201980042886.7A patent/CN112543768B/zh active Active
- 2019-07-10 MY MYPI2020006898A patent/MY202673A/en unknown
- 2019-07-10 BR BR112020026784-8A patent/BR112020026784A2/pt unknown
-
2020
- 2020-12-27 IL IL279803A patent/IL279803A/en unknown
-
2021
- 2021-01-07 MX MX2025013509A patent/MX2025013509A/es unknown
-
2022
- 2022-09-19 US US17/933,185 patent/US12523659B2/en active Active
-
2025
- 2025-04-09 JP JP2025064335A patent/JP2025100662A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012012402A5 (https=) | ||
| JP2021520777A5 (https=) | ||
| JP2019533807A5 (https=) | ||
| JP2018531580A5 (https=) | ||
| JP2014523401A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2013500940A5 (https=) | ||
| RU2013120544A (ru) | Фармацевтическая композиция | |
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2018520668A5 (https=) | ||
| JP2004504808A5 (https=) | ||
| JP2015503909A5 (https=) | ||
| JP2016509585A5 (https=) | ||
| JP7557023B2 (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| JP6564435B2 (ja) | アルファ４ベータ７ヘテロ二量体特異抗体の投与 | |
| JP2015520608A5 (https=) | ||
| JP2021531245A5 (https=) | ||
| JP2020516655A5 (https=) | ||
| JP2017523130A5 (https=) | ||
| IL316308A (en) | Modifying binding molecules to minimize pre-existing interactions | |
| JP6779200B2 (ja) | 川崎病の診断及び治療 | |
| JPWO2020014358A5 (https=) | ||
| US11739388B2 (en) | Phage-based detection of borreliosis and means therefor | |
| CN118085082A (zh) | 抗猫TNF-α单克隆抗体及其应用 | |
| CN113073101B (zh) | 一种心肌肌钙蛋白的寡核苷酸适配体及其应用 |